Amgen has filed a legal action in California state court against Bay Area biosimilar maker Coherus Biosciences, Inc, alleging that since 2014 Coherus has engaged in a “massive conspiracy” to steal trade secrets for Amgen’s reference biologic pegfilgrastim (Neulasta). The drug, a pegylated form of recombinant human granulocyte colony-stimulating factor, is indicated to reduce the incidence of infection in patients with non-myeloid malignancies who are receiving myelosuppressive anticancer agents. Coherus’ biosimilar to pegfilgrastim (CHS-1701) is currently scheduled for a June 9, 2017, regulatory hearing at the FDA concerning its approval.
The lawsuit asserts that Coherus induced multiple Amgen employees to breach confidentiality agreements regarding Amgen’s pipeline in order to gain proprietary knowledge, allegedly receiving such information on “stolen” USB drives. This included sensitive Amgen standard operating procedures, lab notebook pages, validated analytical methods, method development reports, specifications, documents reflecting process optimization work, cost calculators, and pricing and contracting strategies. Amgen is seeking restitution and damages. The lawsuit also names former Amgen employees, including Howard S. Weiser, currently executive director at Coherus, as having violated trade secrets.
Coherus categorically rejected the allegations as baseless and accused Amgen of using the lawsuit to prevent potential competition from the biosimilar product, should it be approved. Danny Lanfear, president and CEO of Coherus, said the action is without merit and the company would defend against it vigorously. “Coherus believes this lawsuit is best understood as an effort by Amgen to use baseless litigation in an effort to delay Coherus as a competitor in the pegfilgrastim market,” he said in a statement.
Lanfear went on to deny that his company needed Amgen’s proprietary information to compete or be successful, adding that he is proud of Coherus’ novel clinical development strategy and novel clinical study designs—none of which were ever performed at Amgen and are not Amgen’s intellectual property. Barclays analysts said the alleged violations occurred well after Coherus developed CHS-1701.
Coherus is also developing a biosimilar of Amgen’s rheumatoid arthritis treatment etanercept (Enbrel) and Abbvie’s adalimumab (Humira).
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.